Antibodies to myelin oligodendrocyte glycoprotein in chronic relapsing inflammatory optic neuropathy.
Adolescent
Adult
Age of Onset
Aquaporin 4
/ immunology
Autoantibodies
/ blood
Child
Chronic Disease
Female
Fluorescent Antibody Technique, Indirect
Glucocorticoids
/ therapeutic use
Humans
Infusions, Intravenous
Magnetic Resonance Imaging
Male
Methylprednisolone
/ therapeutic use
Middle Aged
Myelin-Oligodendrocyte Glycoprotein
/ immunology
Optic Neuritis
/ blood
Recurrence
Tomography, Optical Coherence
Young Adult
inflammation
optic nerve
visual pathway
Journal
The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
received:
29
08
2018
revised:
13
11
2018
accepted:
16
11
2018
pubmed:
6
12
2018
medline:
21
3
2020
entrez:
6
12
2018
Statut:
ppublish
Résumé
To evaluate the status of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in chronic relapsing inflammatory optic neuropathy (CRION) and investigate its different clinical characteristics and prognosis. Patients diagnosed with CRION were recruited by the Neuro-ophthalmology Department of the Chinese People's Liberation Army General Hospital from December 2015 to April 2017. Based on antibody status, they were assigned to either the MOG-CRION or seronegative-CRION groups. A total of 33 patients (38 eyes) were assessed and divided into the following groups: 22 (66.7%) MOG-CRION and 11 (33.3%) seronegative-CRION. The ratio of female to male was 1:1, and 81.8% of total CRION patients were adults (≥18 years). A total of 29 eyes (76.3%) showed severe visual loss (<20/200) during the first optic neuritis episode, and 37 eyes (72.5%) demonstrated good visual recovery (>20/40) during the final follow-up. The mean onset age of MOG-CRION patients was 28 ± 16 years (range 6-62), which was significantly younger than that of seronegative-CRION (45 ± 12 years, range 22-59) (p=0.029). The intraorbital and canalicular segments were highly involved in the orbital MRI of CRION patients. During the final follow-up, MOG-CRION patients had more bilateral involvement (p=0.008) and higher annualised relapse rates compared with the seronegative-CRION patients (p=0.019). CRION was predominantly found in adults with unilateral ON and exhibited a higher rate of seropositive MOG-IgG. MOG-CRION, which may be a disparate subtype of MOG-IgG-induced demyelinating disease that needs further investigation, was found in younger patients at onset, with more bilateral involvement and more relapse tendency.
Sections du résumé
BACKGROUND/AIMS
To evaluate the status of myelin oligodendrocyte glycoprotein antibodies (MOG-IgG) in chronic relapsing inflammatory optic neuropathy (CRION) and investigate its different clinical characteristics and prognosis.
METHODS
Patients diagnosed with CRION were recruited by the Neuro-ophthalmology Department of the Chinese People's Liberation Army General Hospital from December 2015 to April 2017. Based on antibody status, they were assigned to either the MOG-CRION or seronegative-CRION groups.
RESULTS
A total of 33 patients (38 eyes) were assessed and divided into the following groups: 22 (66.7%) MOG-CRION and 11 (33.3%) seronegative-CRION. The ratio of female to male was 1:1, and 81.8% of total CRION patients were adults (≥18 years). A total of 29 eyes (76.3%) showed severe visual loss (<20/200) during the first optic neuritis episode, and 37 eyes (72.5%) demonstrated good visual recovery (>20/40) during the final follow-up. The mean onset age of MOG-CRION patients was 28 ± 16 years (range 6-62), which was significantly younger than that of seronegative-CRION (45 ± 12 years, range 22-59) (p=0.029). The intraorbital and canalicular segments were highly involved in the orbital MRI of CRION patients. During the final follow-up, MOG-CRION patients had more bilateral involvement (p=0.008) and higher annualised relapse rates compared with the seronegative-CRION patients (p=0.019).
CONCLUSION
CRION was predominantly found in adults with unilateral ON and exhibited a higher rate of seropositive MOG-IgG. MOG-CRION, which may be a disparate subtype of MOG-IgG-induced demyelinating disease that needs further investigation, was found in younger patients at onset, with more bilateral involvement and more relapse tendency.
Identifiants
pubmed: 30514710
pii: bjophthalmol-2018-313142
doi: 10.1136/bjophthalmol-2018-313142
doi:
Substances chimiques
AQP4 protein, human
0
Aquaporin 4
0
Autoantibodies
0
Glucocorticoids
0
Myelin-Oligodendrocyte Glycoprotein
0
Methylprednisolone
X4W7ZR7023
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1423-1428Informations de copyright
© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.